NUPATHE INC. 4
Accession 0001209191-14-013765
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 11:15 AM ET
Size
54.9 KB
Accession
0001209191-14-013765
Insider Transaction Report
- Disposition to Issuer
Stock option (right to buy)
2014-02-21$4.78/sh−8,574$40,984→ 0 totalExercise: $2.02Exp: 2021-09-30→ Common Stock (8,574 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.43/sh−6,750$23,153→ 0 totalExercise: $3.37Exp: 2022-06-07→ Common Stock (6,750 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.81/sh−13,500$51,435→ 0 totalExercise: $2.99Exp: 2023-06-05→ Common Stock (13,500 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$4.39/sh−8,631$37,890→ 0 totalExercise: $2.41Exp: 2023-09-30→ Common Stock (8,631 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$5.36/sh−6,238$33,436→ 0 totalExercise: $1.44Exp: 2017-03-29→ Common Stock (6,238 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$4.88/sh−17,467$85,239→ 0 totalExercise: $1.92Exp: 2018-09-11→ Common Stock (17,467 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$4.88/sh−1,247$6,085→ 0 totalExercise: $1.92Exp: 2019-12-09→ Common Stock (1,247 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21−6,014→ 0 totalExercise: $7.75Exp: 2021-03-03→ Common Stock (6,014 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.42/sh−4,906$16,779→ 0 totalExercise: $3.38Exp: 2022-12-31→ Common Stock (4,906 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$5.36/sh−1,871$10,029→ 0 totalExercise: $1.44Exp: 2017-06-07→ Common Stock (1,871 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21−7,486→ 0 totalExercise: $10.00Exp: 2020-08-05→ Common Stock (7,486 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21−6,750→ 0 totalExercise: $7.66Exp: 2021-06-08→ Common Stock (6,750 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$2.77/sh−4,098$11,351→ 0 totalExercise: $4.03Exp: 2022-06-30→ Common Stock (4,098 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.24/sh−4,695$15,212→ 0 totalExercise: $3.56Exp: 2022-09-30→ Common Stock (4,695 underlying) - Disposition to Issuer
Common Stock
2014-02-21$6.80/sh−13,500$91,800→ 0 total - Disposition to Issuer
Stock option (right to buy)
2014-02-21$5.36/sh−6,238$33,436→ 0 totalExercise: $1.44Exp: 2017-01-26→ Common Stock (6,238 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21−2,143→ 0 totalExercise: $7.81Exp: 2021-03-31→ Common Stock (2,143 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21−2,297→ 0 totalExercise: $7.33Exp: 2021-06-30→ Common Stock (2,297 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$4.96/sh−9,431$46,778→ 0 totalExercise: $1.84Exp: 2021-12-30→ Common Stock (9,431 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.10/sh−4,714$14,613→ 0 totalExercise: $3.70Exp: 2022-03-31→ Common Stock (4,714 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.35/sh−3,883$13,008→ 0 totalExercise: $3.45Exp: 2023-03-31→ Common Stock (3,883 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.74/sh−5,513$20,619→ 0 totalExercise: $3.06Exp: 2023-06-30→ Common Stock (5,513 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-02-21$3.53/sh−6,368$22,479→ 0 totalExercise: $3.27Exp: 2023-12-31→ Common Stock (6,368 underlying)
Footnotes (4)
- [F1]Includes all restricted stock units that became fully vested upon the consummation of the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated January 17, 2014, among the issuer, Teva Pharmaceutical Industries Ltd. and Train Merger Sub, Inc.(the "Merger Agreement").
- [F2]Disposed upon the consummation of the Merger in exchange for $3.65 per share, plus contractual rights to receive up to an additional $3.15 in contingent cash consideration payments per share.
- [F3]Pursuant to the Merger Agreement, all options became fully vested upon the consummation of the Merger.
- [F4]Pursuant to the Merger Agremeent, the option was converted into the right to receive, at the earliest date at which the sum of (1) the $3.65 per share cash portion of the merger consideration and (2) the amount per share in cash previously paid or to be paid at such date in connection with the Contingent Cash Consideration Agreement entered into in connection with the Merger Agreement (such sum, the "Per Share Paid Value") exceeds the per-share exercise price under the option: (x) an amount in cash equal to the number of shares of common stock subject to the option multiplied by the excess of (i) the then applicable Per Share Paid Value over (ii) the per-share exercise price under the option; and (y) the right to receive, in respect of each share of common stock subject to the option, each contingent cash consideration payment that, as of such date, has not yet become payable.
Documents
Issuer
NUPATHE INC.
CIK 0001375200
Related Parties
1- filerCIK 0001375200
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 11:15 AM ET
- Size
- 54.9 KB